Clinical trials: Type 2 Diabetes Treated With Insulin
Type 2 Diabetes Mellitus
Real-life Efficacy of Insulia® Tool in Patients Living with Type 2 Diabetes Treated with Basal Insulin Therapy As Part of a National Telemedicine Program (ETAPES)
The purpose of this study was to evaluate the INSULIA digital tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) in a…
- Trial name
- INSULIA (NCT05331339)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Sud Francilien
Type 2 Diabetes Treated With Insulin
Control-IQ Technology in Individuals With Type 2 Diabetes
A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
- Trial name
- 2IQ (NCT05111301)
- Testing
- Control-IQ technology 1.5
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 2 Diabetes Mellitus
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
The purpose of this study is to evaluate the glycemic control and safety of SHR-3167 and Insulin Degludec in type 2 diabetic participants treated with basal insulin with or without oral antidiabetic drugs.
- Trial name
- NCT07018453
- Testing
- SHR-3167, Insulin Degludec
- Where
- 2 sites in China
- Volunteers
- 173 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma
The clinical trial is designed to evaluate the safety of inhaled Technosphere/Insulin compared with non-inhaled anti-diabetic therapies in subjects with type 1 or type 2 diabetes mellitus and concurrent asthma.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
- Trial name
- NCT00332826
- Testing
- Technosphere Insulin
- Where
- 78 sites in United States, Argentina and 9 more
- Volunteers
- 3 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to compare the efficacy and safety of a new basal insulin, insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02106364
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- 10 sites in United States
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Treated With Insulin
C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes
C-peptide is used to evaluate beta cell reserves. Patients with type 2 diabetes are treated with insulin for different indications.
- Trial name
- NCT04005261
- Testing
- C-peptide concentrations
- Where
- Turkey (Türkiye)
- Volunteers
- 249 people
- Sponsor
- Goztepe Training and Research Hospital
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus.
- Trial name
- LIXILAN JP-O1 (NCT02749890)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Lixisenatide (AVE0010), Oral anti-diabetic drugs
- Where
- 61 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Sanofi
Diabetes
Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients
Comparison of efficacy and safety of different insulin regimens between basal bolus and premixed insulin in poorly controlled type 2 diabetes
- Trial name
- COMPAR (NCT02219750)
- Testing
- switch twice-daily insulin
- Where
- Taiwan
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Diabetes, Diabetes Mellitus, Type 2
Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type 2 diabetes, not well…
- Trial name
- NCT00184561
- Testing
- biphasic insulin aspart
- Where
- 8 sites in China
- Volunteers
- 321 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to…
- Trial name
- 4T (NCT00184600)
- Testing
- biphasic insulin aspart, insulin detemir, insulin aspart
- Where
- 63 sites in Ireland, United Kingdom
- Volunteers
- 708 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with…
- Trial name
- NCT01880736
- Testing
- insulin degludec
- Where
- 40 sites in Japan
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.
- Trial name
- NCT01027871
- Testing
- LY2605541, insulin glargine
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 289 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart
This trial is conducted in Asia. The aim of this trial is evaluate the remission rate in newly diagnosed subjects with type 2 diabetes after short-term intensive treatment with insulin aspart and insulin NPH.
- Trial name
- NCT00494988
- Testing
- insulin aspart, insulin NPH
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Anxiety Reduction in Type 2 Diabetes Through Breathing ExercisesPatients With Type 2 Diabetes
Injection-related anxiety is a significant barrier to the management of type 2 diabetes, adversely affecting treatment adherence and glycemic control.
- Trial name
- NCT06519903
- Testing
- BREATH technique
- Where
- Turkey (Türkiye)
- Volunteers
- 65 people
- Sponsor
- Goztepe Prof Dr Suleyman Yalcın City Hospital
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Evaluation of Diabetes and WELLbeing Programme
This study evaluates the impact of 'DWELL' - a 12-week psycho-social education programme designed to help people with type 2 diabetes to better self-manage their condition.
- Trial name
- DWELL (NCT04274660)
- Testing
- DWELL (Diabetes and WELLbeing) Programme
- Where
- 5 sites in Belgium, France and 2 more
- Volunteers
- 594 people
- Sponsor
- Canterbury Christ Church University
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
This study is conducted in Europe. This observational study is aimed to reflect the post-authorisation experience with insulin analogue (biphasic insulin aspart 30) when used under normal clinical practice conditions in Serbia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- EFFECTIVE (NCT00699179)
- Testing
- biphasic insulin aspart 30
- Where
- Serbia and Montenegro
- Volunteers
- 2,308 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin.
- Trial name
- CONTROL (NCT07057479)
- Testing
- Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Type 2 Diabetes Mellitus
Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the ability of a patient, who has type 2 diabetes (T2DM) who is currently treated with basal/bolus insulin therapy, to use PaQ™ (a simple patch on insulin delivery device) to control…
- Trial name
- NCT01535612
- Testing
- PaQ™ insulin infusion device
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- CeQur Corporation
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
This trial is conducted in Europe, Africa and the United States of America (USA). The aim of this trial is to compare the safety and efficacy of two different insulin treatments, the "basic" and the "advanced" treatment in type 2…
- Trial name
- NCT00537303
- Testing
- insulin detemir, insulin aspart
- Where
- 69 sites in United States, Denmark and 10 more
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin
Dual combination therapy with metformin and sulphonylurea is the most commonly used combination regimen to treat patients with type 2 diabetes.
- Trial name
- NCT01099137
- Testing
- Vildagliptin, Sulphonylurea dose-up
- Where
- South Korea
- Volunteers
- 344 people
- Sponsor
- Seoul National University Bundang Hospital